Subscribers to Schaeffer's Weekend Trader options recommendation service received this HIMS commentary on Sunday night, along with a detailed options trade recommendation -- including complete entr...

Should You Buy Hims & Hers Stock on the Dip?

Hims & Hers stands out from Teladoc by focusing on direct-to-consumer telehealth services, contrasting Teladoc's business-to-business model. This telehealth company provides personalized treatments...

H&H's strong Q3 results signals a fundamental shift in the healthcare industry. GLP-1 drugs are certainly a growth catalyst for H&H but it is just a tiny component of the overall investment thesis....

Hims & Hers is a rapidly emerging player in telehealth and wellness, catering to millennials and Gen Z. The company reported a 77% year-over-year revenue growth, with a subscriber base of 2 million...

Hims & Hers strong performance involves much more than just GLP-1 drugs.

Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, t...

We don't expect any sudden movements in the stock market until Wednesday morning the earliest.

The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the third quarter.

GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is.

Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. The company benefits from GLP-1 drug sales and is posit...

Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?

Look beyond the stock price at the business when shares are volatile.

Consistently investing even moderate sums can grow your portfolio with time.

Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...